Monotherapy versus combination therapy for the treatment of chronic hepatitis B. (Q37620354)

21 August 2017

1 reference

title

Monotherapy versus combination therapy for the treatment of chronic hepatitis B. (English)

1 reference

21 August 2017

1 reference

Ivana Carey

1

1 reference

21 August 2017

Phillip M Harrison

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

18

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1655-1666

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Understanding the molecular basis of HBV drug resistance by molecular modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Antiviral drug resistance: clinical consequences and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Complex dynamics of hepatitis B virus resistance to adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Entecavir: a potent new antiviral drug for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Inhibition of hepatitis B virus polymerase by entecavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Tenofovir-induced kidney injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Clinical features of adverse reactions associated with telbivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543780903241599

10.1517/13543780903241599

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference